Neos Therapeutics

Neos Therapeutics is an oral drug delivery company developing controlled time-release technologies. The Company develops, manufactures, and commercializes innovative extended-release products using its proprietary extended-release drug delivery and orally disintegrating tablet (ODT) technology platforms. 

Neos Therapeutics has two FDA-approved products for the treatment of ADHD and both utilize its extended-release ODT technology.

The Company's growing ADHD Product Portfolio puts Neos in a unique position to meet the different needs of patients that struggle with ADHD.

Company Growth (employees)
Type
Public
HQ
Grand Prairie, US
Founded
2008
Size (employees)
134 (est)+66%
Website
neostx.com
Neos Therapeutics was founded in 2008 and is headquartered in Grand Prairie, US

Neos Therapeutics Office Locations

Neos Therapeutics has offices in Grand Prairie and Blue Bell
Grand Prairie, US (HQ)
2940 N. Highway 360
Blue Bell, US
130 1787 Sentry Pkwy W

Neos Therapeutics Data and Metrics

Neos Therapeutics Financial Metrics

Neos Therapeutics's revenue was reported to be $9.2 m in FY, 2016
USD

Net income (Q1, 2017)

(17.1 m)

EBIT (Q1, 2017)

(15 m)

Market capitalization (25-Jul-2017)

134.4 m

Cash (31-Mar-2017)

43.7 m
Neos Therapeutics's current market capitalization is $134.4 m.
USDFY, 2015FY, 2016

Revenue

3.8 m9.2 m

Revenue growth, %

141%

Cost of goods sold

5.5 m11.4 m

Gross profit

(1.8 m)(2.3 m)

Gross profit Margin, %

(46%)(25%)

R&D expense

11.9 m12.2 m

General and administrative expense

7.5 m12.6 m

Operating expense total

19.4 m24.8 m

EBIT

(26.6 m)(76.4 m)

EBIT margin, %

(701%)(835%)

Interest expense

(3.7 m)(6.9 m)

Net Income

(30.8 m)(83.3 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

1.5 m221 k

Cost of goods sold

2.3 m1.7 m2.3 m4.6 m

R&D expense

2.1 m2.7 m2.3 m4.3 m2.9 m1.7 m

General and administrative expense

1.7 m2.1 m3.6 m3.5 m3.1 m3.5 m

Operating expense total

3.8 m4.8 m5.9 m7.8 m6.1 m5.3 m

EBIT

(4.5 m)(7 m)(11.9 m)(24 m)(23.7 m)(15 m)

EBIT margin, %

(306%)(3156%)

Interest expense

(884 k)(1 m)(961 k)(1.5 m)(2.1 m)(2.2 m)

Net Income

(5.8 m)(9.4 m)(12.6 m)(26.5 m)(25.8 m)(17.1 m)
USDFY, 2015FY, 2016

Cash

90.8 m24.4 m

Accounts Receivable

1.2 m

Inventories

2.5 m5.8 m

Current Assets

98.2 m55.3 m

PP&E

5.1 m7.1 m

Total Assets

122.5 m80.1 m

Accounts Payable

4.8 m7.8 m

Total Debt

34.2 m63.5 m

Current Liabilities

15.9 m21.6 m

Non-Current Liabilities

28.2 m60 m

Total Liabilities

44.1 m81.7 m

Additional Paid-in Capital

195.3 m198.8 m

Retained Earnings

(116.8 m)(200.1 m)

Total Equity

78.4 m(1.5 m)

Debt to Equity Ratio

0.4 x-41 x

Debt to Assets Ratio

0.3 x0.8 x

Financial Leverage

1.6 x-51.8 x
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

25.6 m102.9 m42.4 m41.9 m43.5 m43.7 m

Inventories

1.7 m2.7 m2.5 m4.4 m5.7 m5.6 m

Current Assets

29.7 m106.4 m93.1 m91.9 m72 m74.7 m

PP&E

5.3 m5.2 m5.4 m6.8 m7 m7 m

Total Assets

55.9 m131.1 m117.9 m117.7 m97.4 m99 m

Accounts Payable

1.3 m2.4 m3.5 m3.3 m7.8 m7 m

Current Liabilities

7 m13.2 m17.9 m16.8 m21.4 m26 m

Non-Current Liabilities

37.6 m30.9 m33.5 m60.2 m60.1 m60.4 m

Additional Paid-in Capital

5.1 m194.7 m195.9 m196.8 m197.8 m230 m

Retained Earnings

(98.1 m)(107.7 m)(129.4 m)(155.9 m)(181.7 m)(217.2 m)

Total Equity

(93 m)87 m66.4 m40.7 m15.9 m12.6 m

Financial Leverage

-0.6 x1.5 x1.8 x2.9 x6.1 x7.9 x
USDFY, 2015FY, 2016

Net Income

(30.8 m)(83.3 m)

Accounts Receivable

(2.2 m)

Inventories

2.5 m(3.2 m)

Accounts Payable

4.8 m3 m

Cash From Operating Activities

(70.6 m)

Capital Expenditures

(3.6 m)

Cash From Investing Activities

(19.3 m)

Cash From Financing Activities

23.6 m

Interest Paid

2.9 m

Free Cash Flow

(74.2 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(5.8 m)(9.4 m)(12.6 m)(26.5 m)(25.8 m)(17.1 m)

Inventories

1.7 m2.7 m2.5 m4.4 m5.7 m5.6 m

Accounts Payable

1.3 m2.4 m3.5 m3.3 m7.8 m7 m
Y, 2017

Financial Leverage

7.9 x

Neos Therapeutics Market Value History

Neos Therapeutics News and Updates

Neos Therapeutics Company Life and Culture

You may also be interested in